BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Renovo Ltd. Announces The Appointment Of Dr. Carl Peck To Its Scientific And Clinical Advisory Board


10/19/2005 5:08:45 PM

Renovo today announced the appointment of Dr Carl Peck to its Scientific and Clinical Advisory Board. Professor of Pharmacology at the Georgetown University Medical Center, Dr Peck is the Chairman and Founder of NDA Partners LLC, the Founder and Director of Georgetown University Center for Drug Development Science (CDDS), a former Director of the FDA’s Center for Drug Evaluation and Research (CDER) and Assistant Surgeon General of the United States. Dr Peck was Director of the US FDA’s Center for Drug Evaluation and Research from 1987 – 1993, where he was praised for having brought to the FDA “the spirit of innovative scientific management”. He founded the Georgetown University CDDS, where he has researched drug development issues and taught since 1994. Important methodologies, championed by CDDS include PBPK modelling, simulation of clinical trials, and the theory of scientific drug development that optimises causal and empirical information to enable efficient transition of promising agents to useful therapeutic drugs. Dr Peck led and contributed to many innovations at the FDA, including the Subpart E and accelerated approval regulations, employment of surrogate endpoints, and efficient dossier review procedures. In 2000, Dr Peck was awarded the FDA Distinguished Alumnus Award and in 2002 an Honorary Doctorate degree by Uppsala University for “Outstanding Contributions to the Science of Drug Development”.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES